58 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27983846	66	Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.	University of Bath
28001384	189	Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.	Health & Science University
28001064	16	Recent Advances in Scaffold Hopping.	Rheinische Friedrich-Wilhelms-Universit£T
27163581	110	Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.	University of Bath
26985304	23	Potential Use of Inhibitors of Tankyrases and PARP-1 as Treatment for Cancer and Other Diseases.	Therachem Research Medilab (India)
26706174	46	Development and structural analysis of adenosine site binding tankyrase inhibitors.	University of Oulu
26183543	87	Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.	University of Oulu
26026769	24	Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.	University of Bath
26061013	55	Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.	Philochem
25847770	4	Structure-activity relationship and properties optimization of a series of quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway.	Siena Biotech
25680029	12	Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen.	The Institute of Cancer Research
24527792	8	Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.	Universit£
24900625	52	Design and Discovery of 2-Arylquinazolin-4-ones as Potent and Selective Inhibitors of Tankyrases.	University of Bath
23574272	30	Screening and structural analysis of flavones inhibiting tankyrases.	University of Oulu
23473363	12	Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.	Oslo University Hospital
23316926	12	Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.	Amgen
22233320	19	Structural basis of selective inhibition of human tankyrases.	Abo Akademi University
22260203	73	[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding.	Novartis Institutes For Biomedical Research
20565110	7	Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor.	Karolinska Institutet
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
32944134	12	Novel 4-Heteroarylcarbonyl-N-(phenyl or heteroaryl) Piperidine-1-carboxamides as Tankyrase Inhibitors.	Lauren Mccallister
32511917	79	Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.	University of Oslo
32435397	31	From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.	University of Naples
30684797	32	Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.	Nirma University
30883102	214	Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.	Riken
32202790	160	Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.	Japanese Foundation For Cancer Research
31381853	124	Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.	Merck Healthcare
30655950	116	Rational Design of Cell-Active Inhibitors of PARP10.	Oregon Health and Science University
26546219	47	Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.	Astrazeneca
26396691	20	Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors.	Hoffmann-La Roche
25299683	13	Scaffold hopping approach on the route to selective tankyrase inhibitors.	University of Perugia
24900768	10	Tankyrase inhibitors: potential treatment of hyperproliferative diseases.	Therachem Research Medilab (India)
31042381	166	Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity.	St. John'S University
30006177	103	4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.	University of Oulu
29969256	21	Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction.	Universitaire Vaudois
29107427	13	Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.	University of Perugia
29934219	8	Identification by Inverse Virtual Screening of magnolol-based scaffold as new tankyrase-2 inhibitors.	University of Salerno
29856625	43	Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.	University of Pennsylvania
29748053	87	Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14.	Mcdaniel College
29155568	29	Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.	Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)
26895387	24	Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.	Stony Brook University
18800822	40	4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.	Kudos Pharmaceuticals
19111460	94	Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.	Boehringer Ingelheim Pharmaceuticals
16337119	48	Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase.	Academy of Sciences of The Czech Republic